The evaluation of EpCAM expression in the context of clinicopathological and molecular features demonstrated that—depending on the tumor type—both upregulation and reduced expression of EpCAM can be associated with unfavorable tumor features and tumor progression. Here, EPCAM is linked to neoplasm.